Search
![](/contentassets/a94b5755a9754ad287103240f25e8189/intro-session.jpg)
News & Events
Expert researchers converge on Broome to tackle health challenges in Northern AustraliaOver 100 researchers and health professionals from around Australia have united in Broome this week to address the major health battles facing people living in the tropical north of the country.
![](/globalassets/media/images/pagessections/people-profiles/a/7.png)
People
Ingrid Amgarth-DuffDr Amgarth-Duff is an early career Post-doctoral Senior Research Offer in the Healthy Skin & ARF prevention team.
Research
Cellulitis in children: A retrospective single centre study from AustraliaTo characterise the epidemiology, clinical features and treatment of paediatric cellulitis. Methods A retrospective study of children presenting to a paediatric tertiary hospital in Western Australia, Australia in 2018.
Research
Antibiotic treatment duration for bloodstream infections in critically ill children - A survey of pediatric infectious diseases and critical care clinicians for clinical equipoiseTo describe antibiotic treatment durations that pediatric infectious diseases (ID) and critical care clinicians usually recommend for bloodstream infections in critically ill children.
Research
Predicting the causative pathogen among children with osteomyelitis using Bayesian networks – improving antibiotic selection in clinical practiceWe have demonstrated the potential use of Bayesian Networks in improving antibiotic selection for children with osteomyelitis
Research
Planning and clinical role of acute medical home care services for COVID-19: consensus position statement by the Hospital-in-the-Home Society AustralasiaDuring a pandemic when hospitals are stretched and patients need isolation, the role of hospital-in-the-home (HITH) providing acute medical care at home has never been more relevant. We aimed to define and address the challenges to acute home care services posed by the COVID-19 pandemic.
Research
COVID-19, children and schools: overlooked and at riskWe have closely followed the international literature about severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) transmission dynamics in children (aged 0–18 years).2 Evidence‐informed discussion about school attendance in the context of COVID‐19 is a high priority and this complex subject requires weighted expert review of the literature to accurately inform policy. As paediatricians and infectious diseases specialists, we wish to highlight important considerations when interpreting the available data.
Research
Case Report: Neonatal Varicella Acquired From Maternal ZosterThe incidence of neonatal varicella has decreased dramatically since the introduction of the varicella vaccination. Although the varicella zoster virus is often associated with a mild infection, it may cause severe morbidity and mortality, particularly in the neonatal period and immunocompromised hosts. We report a case of neonatal varicella acquired from maternal zoster in a mother on biological immunosuppressive therapy.
Research
Modes of transmission and attack rates of group A Streptococcal infection: a protocol for a systematic review and meta-analysisGroup A Streptococcus (Strep A) is an important cause of mortality and morbidity globally. This bacterium is responsible for a range of different infections and post-infectious sequelae. Summarising the current knowledge of Strep A transmission to humans will address gaps in the evidence and inform prevention and control strategies. The objective of this study is to evaluate the modes of transmission and attack rates of group A streptococcal infection in human populations.
Research
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospitalItraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.